Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Solid Tumors 1Pancreatic Neoplasms 1Haematological Malignancies 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × MSC1992371A × Clear all
NCT00391521 2014-01-30

AS703569 Phase I in Patients With Solid Tumours

EMD Serono

Phase 1 Completed
104 enrolled
Other solid neoplasm

Solid Tumors

NCT01097512 2014-01-30

AS703569 and Gemcitabine Combination in Advanced Malignancies

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
66 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01080664 2013-10-22

A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

EMD Serono

Phase 1 Terminated
124 enrolled

Haematological Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡